To include your compound in the COVID-19 Resource Center, submit it here.

With new CEO, $55M A round, Locana readies RNA-targeting gene therapy for clinic

As it evolves beyond Cas9, Locana plans to leverage Arch-led series A to bring its first RNA-targeting gene therapy into clinic for genetic repeat expansion diseases

Preclinical data supporting its RNA-targeting gene therapy platform enabled Locana to attract $55 million in series A funding led by existing investor Arch Venture Partners, which the San Diego company plans to use to bring its first therapy into the clinic for genetic repeat expansion diseases.


Read the full 475 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers